Biotech and pharmaceutical companies go through various challenges that are interesting yet tough in the digitalization era. While new innovations have increased chances for measure upgrades, regulatory oversight has eased back reception comparative with different industries. Firm requirements for process validation, data integrity, and documentation establish an environment where compliance can exceed sustainable improvement. The growing advances that portray Industry 4.0 from advanced analytics to connectivity, network, automation, and robotics have the competency to alter each component of pharma business. Although it is just the beginning of industry 4.0 in the pharmaceutical field a number of the manufacturer are already making the most out of it.

The Digital era has been a boon to the industry. But pharma manufacturers deal with increasingly complex challenges in this digital era. Pharma manufacturers need a holistic approach to increase quality, safety, transparency, agility, and productivity. Pharma 4.0TM, a term coined by ISPE (International Society for Pharmaceutical Engineering) is a concept adopted from Industry 4.0. The concept aims to bring in an interactive system, analytical data, advanced automation, and a simplified regulatory framework.

In our top 10 of 2021, a recap of Pharma 4.0 sheds light on what technologies the life sciences industries can take advantage of. The article covers talks given by experts at the PDA Annual Meeting, and includes discussion of digitalizing paper records, making the most of data, and how AI can models can boost regulatory compliance. Paper is cumbersome and time-consuming, placing additional unneeded demands on the workforce, yet factories–and especially those in pharma–still rely heavily on its use. Referencing the Pharma 4.0 pillars, Langer pointed out that digitally native workers come into the workplace only to be brought into a culture which teaches them to use organization and processes that are centered on paper. This is a waste of ability to help transition into the digital era and serves only to create a workforce gap.

The development stage can be one of the most expensive and critical in the life sciences value chain, and is often bogged down in an oversight process that is highly manual and paper based. A clinical-stage study costs an average of $1.1 billion over 6.6 years, according to EY, and so any potential for increasing speed and efficiency in biopharmaceuticals development can have a dramatic impact on the bottom line. Luckily, we're now in the era of the smart connected lab, with robotic process automation (RPA) software deployed to transform the very nature of clinical development. James Ewing, UK regional director of Digital Workforce, says automation is changing pharmaceutical manufacturing in three key ways: streamlining operations through automating high-volume, low-value repetitive tasks, such as comparing datasets; helping researchers increase accuracy when dealing with large quantities of data; and cutting down the administrative tasks associated with regulation. "Given that biopharma research is a heavily regulated industry, there is a large amount of internal documentation which needs to be updated and submitted to external parties. This compliance paperwork process is time consuming, but can be easily automated using RPA," he says.